17,261 trials
Multiple Myeloma
Primary: Percentage of Participants With Adverse Events (AEs) — 100.0; 100.0; 100.0; 100.0 Percentage of Participants
Alzheimer Disease · Parkinson Disease
Primary: Percentage of Participants With Treatment-Emergent Adverse Events — 3; 5; 4; 6 Participants
Congenital Heart Disease · Periventricular Leucomalacia · Brain Development
Primary: Motor Scale of the Bayley Scales of Infant and Toddler Development-III — 90.0; 87.5; 88.7 score on a scale
Post-Traumatic Stress Disorder
Primary: Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score — 15.26…
Covid19
Primary: Primary Hierarchical Composite Endpoint — 5.32; 5.33 Ranked Severity Score
Myocardial Infarction
Primary: Left Ventricular Ejection Fraction Assessed by Cardiac Magnetic Resonance Imaging (CMRI) — 5.6; 5.3; 5.7 percentage of left ventricular volumes
Cognitive Impairments Associated With Schizophrenia
Primary: Change in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 28.15; 25.22; 31.71; 28.3 score on scale
Acute Myeloid Leukemia
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
HIV-1 Infection
Primary: Area Under the Plasma Drug Concentration-time Curve From 0 to 24 Hours Post-dose (AUC0-24) of Islatravir (ISL) — 0.114 hr*µmol/L
Relapsed/Refractory · Multiple Myeloma
Primary: Phase 1: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 4; 3; 12; 22 Participants
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Rectal Cancer
Primary: Number of Patients With Pathologic Complete Response — 0; 2 Participants
Fallopian Tube Carcinoma · Ovarian Carcinoma · Primary Peritoneal Carcinoma
Primary: To Determine the Safety and Evaluate Toxicity of Fixed Doses for Phase I Patients — 1 Participants
Non-small Cell Lung Cancer
Primary: Number of Participants With a Change From Baseline in Ventilation Map Using Hyperpolarized Xe-129 MR Imaging — 6 Participants — p=0.041
Cannabis Dependence
Primary: Change in Marijuana Withdrawal Checklist (MWC) — 6.04; 11 score on a scale